Literature DB >> 23839587

Update on late-night salivary cortisol for the diagnosis of Cushing's syndrome: methodological considerations.

Hershel Raff1.   

Abstract

Late-night salivary cortisol (LNSC) is now considered the best approach to screen patients suspected of having endogenous hypercortisolism (Cushing's syndrome). As the use of LNSC increases, new preanalytic and analytic issues have arisen. The routine immunoassay for salivary cortisol seems to have better diagnostic performance than liquid chromatograph/tandem mass spectrometry, although measurement of normal salivary cortisone concentrations with the latter technique is very useful in identifying samples contaminated with topical hydrocortisone. LNSC is very useful in screening for Cushing's syndrome in women with increased corticosteroid-binding globulin resulting from estrogen therapy or pregnancy. Two LNSCs from each patient is recommended for routine screening, although one adequate saliva sample seems to perform well. The overnight dexamethasone suppression test remains superior to LNSC in the evaluation of potential subclinical hypercortisolism in patients with adrenal incidentalomas. Periodic assessment of LNSC is extremely useful in monitoring patients for recurrence of Cushing's disease after pituitary surgery. With the large increase in the number LNSCs being ordered around the world, it is likely that more preanalytic and analytic issues will arise, which laboratorians and clinical chemists will need to resolve.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839587     DOI: 10.1007/s12020-013-0013-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  28 in total

1.  Simultaneous quantitative analysis of salivary cortisol and cortisone in Korean adults using LC-MS/MS.

Authors:  Sanghoo Lee; Soonho Kwon; Hye-Jin Shin; Hwan-Sub Lim; Ravinder J Singh; Kyoung-Ryul Lee; Young-Jin Kim
Journal:  BMB Rep       Date:  2010-07       Impact factor: 4.778

Review 2.  Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications.

Authors:  Warrick J Inder; Goce Dimeski; Anthony Russell
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

3.  Salivary cortisone is a potential biomarker for serum free cortisol.

Authors:  I Perogamvros; B G Keevil; D W Ray; P J Trainer
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

4.  Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues.

Authors:  R E Smith; J A Maguire; A N Stein-Oakley; H Sasano; K Takahashi; K Fukushima; Z S Krozowski
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

5.  Late-night salivary cortisol as a screening test for Cushing's syndrome.

Authors:  H Raff; J L Raff; J W Findling
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

6.  Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol.

Authors:  Luca Manetti; Giuseppe Rossi; Lucia Grasso; Valentina Raffaelli; Ilaria Scattina; Simone Del Sarto; Mirco Cosottini; Aldo Iannelli; Maurizio Gasperi; Fausto Bogazzi; Enio Martino
Journal:  Eur J Endocrinol       Date:  2013-02-15       Impact factor: 6.664

7.  The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma.

Authors:  Benedetta Masserini; Valentina Morelli; Silvia Bergamaschi; Federica Ermetici; Cristina Eller-Vainicher; Anna Maria Barbieri; Maria Antonia Maffini; Alfredo Scillitani; Bruno Ambrosi; Paolo Beck-Peccoz; Iacopo Chiodini
Journal:  Eur J Endocrinol       Date:  2008-10-03       Impact factor: 6.664

8.  Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis.

Authors:  Ty Carroll; Hershel Raff; James W Findling
Journal:  Endocr Pract       Date:  2009 May-Jun       Impact factor: 3.443

9.  Midnight salivary cortisol determination for assessing the outcome of transsphenoidal surgery in Cushing's disease.

Authors:  Carmen A Carrasco; Joël Coste; Laurence Guignat; Lionel Groussin; Marie Annick Dugué; Stéphane Gaillard; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2008-08-26       Impact factor: 5.958

10.  Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas.

Authors:  Timo Deutschbein; Nicole Unger; Jakob Hinrichs; Martin K Walz; Klaus Mann; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2009-09-02       Impact factor: 6.664

View more
  25 in total

1.  The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study.

Authors:  L Trementino; M Zilio; G Marcelli; G Michetti; M Barbot; F Ceccato; M Boscaro; C Scaroni; G Arnaldi
Journal:  Endocrine       Date:  2014-12-11       Impact factor: 3.633

2.  Interference in ACTH immunoassay negatively impacts the management of subclinical hypercortisolism.

Authors:  Serkan Yener; Leyla Demir; Mustafa Demirpence; Mustafa Mahmut Baris; Ilgin Yildirim Simsir; Secil Ozisik; Abdurrahman Comlekci; Tevfik Demir
Journal:  Endocrine       Date:  2017-02-28       Impact factor: 3.633

3.  Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus?

Authors:  Hershel Raff; Steven B Magill
Journal:  Endocrine       Date:  2016-09-30       Impact factor: 3.633

4.  Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Annamaria De Bellis; Maria Teresa Vietri; Carmela Mosca; Lorenzo Scappaticcio; Daniela Pasquali; Katherine Esposito; Dario Giugliano
Journal:  Endocrine       Date:  2015-10-28       Impact factor: 3.633

Review 5.  Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations.

Authors:  Laura Trementino; Marina Cardinaletti; Carolina Concettoni; Giorgia Marcelli; Marco Boscaro; Giorgio Arnaldi
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

6.  DHEAS for the prediction of subclinical Cushing's syndrome: perplexing or advantageous?

Authors:  Serkan Yener; Hamiyet Yilmaz; Tevfik Demir; Mustafa Secil; Abdurrahman Comlekci
Journal:  Endocrine       Date:  2014-08-22       Impact factor: 3.633

Review 7.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

8.  Characterization of the serum and salivary cortisol response to the intravenous 250 µg ACTH1-24 stimulation test.

Authors:  Brendan J Nolan; Jane Sorbello; Nigel Brown; Goce Dimeski; Warrick J Inder
Journal:  Endocrine       Date:  2018-01-03       Impact factor: 3.633

Review 9.  Harmful effects of functional hypercortisolism: a working hypothesis.

Authors:  Giacomo Tirabassi; Marco Boscaro; Giorgio Arnaldi
Journal:  Endocrine       Date:  2013-11-27       Impact factor: 3.633

Review 10.  Cushing's syndrome: from physiological principles to diagnosis and clinical care.

Authors:  Hershel Raff; Ty Carroll
Journal:  J Physiol       Date:  2015-01-05       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.